The eISF, or electronic Investigator Site File, is the digital version of the paper-based investigator site file (ISF). It enables the collection in digital form of essential documents that demonstrate a clinical trial was conducted in accordance with Good Clinical Practice (GCP) guidelines, as well as regulatory and sponsor requirements. These documents include the protocol, informed consent forms, study reports, lab results, and other documentation related to the trial.
Leads to this page The use of eISFs has several advantages over paper-based ISFs :
• efficiency in document management
• increases accuracy and completeness of data
• enhances security of sensitive information
• facilitates remote monitoring of study sites
• real-time data access and sharing between sites, sponsors, and regulatory agencies
Theuse of eISFs represents a significant step forward in the conduct of clinical research, enabling faster and more efficient trial management while ensuring compliance with regulatory and ethical standards.
January 30, 2025
MedtechDive Artificial intelligence was a topic of focus for the medical device industry in 2024. Companies including GE Healthcare, Medtronic and Dexcom touted new AI features, and others like Stryker and Quest Diagnostics added AI assets through M&A. Meanwhile, conversations about regulations and generative AI, models that are trained to create new data including images and text, dominated medtech conferences. The Food and Drug Administration recently […]
January 30, 2025
BioPharm International FDA published a final guidance on Jan. 2, 2025 for those interested in participating in the agency’s Advanced Manufacturing Technologies Designation Program, which was developed to facilitate drugs manufactured using advanced manufacturing technologies (AMTs). The guidance, Advanced Manufacturing Technologies Designation Program, is the final version of the draft document issued on Dec. 13, 2023. […]
January 30, 2025
Applied Clinical Trials Online Medable has shared new data from the Tufts Center for the Study of Drug Development (CSDD)’s PACT Consortium linking decentralized clinical trial (DCT) approaches to a higher rate in participation across multiple demographic groups. The new research shows that a more strategic implementation of DCT elements, combined with increased regulatory oversight, […]